Immunomodulator-Mycobacterium Cell Wall Fraction as an aid in control of persistent Mycoplasma bovis infection in dairy cows

Main Article Content

Aleksandar Masic
Bojana Prunic
Dejan Bugarski
Tamas Petrovic
Jelena Apic
Tomislav Barna
Aleksandar Milovanovic

Abstract

Mycoplasma bovis is pathogen known to cause respiratory disease, otitis media, arthritis and a variety of additional diseases in cattle. Infections caused by this pathogen have significant impact on the health, welfare and productivity of dairy and beef cattle resulting in substantial economic losses. Current preventive and treatment strategies rely on the use of antimicrobials and vaccines; however, their efficacy is limited due to difficult diagnosis and inconsistent disease expression. Here, we report results on the use of Mycobacterium cell wall fraction (MCWF), an immunomodulator, in dairy cows persistently infected with M. bovis during the period 2011-2015. Application of MCWF aided in reducing M. bovis-associated clinical signs, such as pneumonia, arthritis and mastitis, and improving overall reproductive performance and days in lactation of infected dairy cows. These results were compared to historical information on the health status and farm performance for period 2011-2015, and suggest that MCWF immunomodulator could be introduced as an aid in treatment protocols for persistent infections with M. bovis in dairy cows.

Downloads

Download data is not yet available.

Article Details

How to Cite
Masic, A., Prunic, B., Bugarski, D., Petrovic, T., Apic, J., Barna, T., & Milovanovic, A. (2017). Immunomodulator-Mycobacterium Cell Wall Fraction as an aid in control of persistent Mycoplasma bovis infection in dairy cows. Veterinarski Glasnik, 71(1), 58–68. https://doi.org/10.2298/VETGL170308003M
Section
Case Report

References

Azuma, I. 1992. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine, 10:1000-1006. http://dx.doi. org/10.1016/0264-410X(92)90108-V.

Filion M. C. & Phillips, N. C. 2001. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opinion on Investigational Drugs, 10:2157-2165. http://dx.doi.org/10.1517/13543784.10.12.2157.

Gagea M. I., Bateman, K. G., Shanahan, R. A., van Dreumel, T., McEwen, B. J., Carman,S., Archambault, M., Caswell, J. L. 2006. Naturally occurring Mycoplasma bovis-associated pneumonia and polyarthritis in feedlot beef calves. Journal of Veterinary Diagnostic Investigation, 18:29-40.

Jungi T. W., Krampe, M., Sileghem, M., Griot, C., Nicolet, J. 1996. Differential and strainspecifictriggering of bovine alveolar macrophage effector functions by mycoplasmas. Microbial Pathogenesis, 21:487-498. http://dx.doi.org/10.1006/mpat.1996.0078.

Le Garrec, Y. 1986. Immunomodifiers of bacteria. Comparative Immunology, Microbiology andInfectious Diseases, 9:137-141. http://dx.doi.org/10.1016/0147-9571(86)90005-6.

Madonna, G. S., Ledney, G. D., Elliott, T. B., Brook, I., Ulrich, J. T., Meyers, K. R., Patchen, M. L., Walker, R. I. 1989. Trehalose dimycolate enhances resistance to infection in neutropenic animals. Infection and Immunity, 57:2495–2501.

Maunsell, F. P., Woolums, A. R., Francoz, D., Rosenbusch, R. F., Step, D. L., Wilson, D. J.,Janzen, E. D. 2011. Mycoplasma bovis infections in cattle. Journal of Veterinary Internal Medicine, 25:772-783. DOI: 10.1111/j.1939-1676.2011.0750.x.

Nishizawa, M., H. Yamamoto, H. Imagawa, V. Barbier-Chassefiere, E. Petit, I. Azuma, and D. Papy-Garcia. 2007. Efficient syntheses of a series of trehalose dimycolate (TDM)/ trehalose dicorynomycolate (TDCM) analogues and their interleukin-6 level enhancement activity in mice sera. Journal of Organic Chemistry, 72:1627-1633. DOI: 10.1021/jo062018j.

O’Reilly, T. & Zak O. 1992. Enhancement of the Effectiveness of Antimicrobial Therapy byMuramyl Peptide Immunomodulators. Clinical and Infectious Diseases, 14:1100-1109. https:// doi.org/10.1093/clinids/14.5.1100.

Rogan, D., Fumuso, E., Rodrıguez, E., Wade, J., Sanchez Bruni, S. F. 2007. Use of a mycobacterialcell wall extract (MCWE) in susceptible mares to clear experimentally induced endometritis with Streptococcus zooepidemicus. Journal of Equine Veterinary Science, 27:112-117. http:// dx.doi.org/10.1016/j.jevs.2007.01.010.

Romanowski, R., Rick, C., Alkemade, S., Medellin-Peña, M. J., Bugarski, D., Milovanovic, A., Nesic, S., Masic, A. 2017. Mycobacterium Cell Wall Fraction Immunostimulant (Amplimune™) efficacy in reduction of severity of ETEC induced diarrhea in neonatal calves, Acta Veterinaria-Beograd, 2017, 67(2), DOI: 10.1515/acve-2017-0019.

Thomas, C. B., Van Ess, P., Wolfgram, L. J., Riebe, J., Sharp, P., Schultz, R. R. 1991. Adherence to bovine neutrophils and suppression of neutrophil chemiluminescence by Mycoplasma bovis. Veterinary Immunology and Immunopathology, 27:365-381. http://dx.doi.org/10.1016/0165- 2427(91)90032-8.

Traub, S., von Aulock, S., Hartung, T., Hermann, C. 2006. MDP and other muropeptides -direct and synergistic effects on the immune system. Journal of Endotoxin Research, 12:69-85.

Most read articles by the same author(s)